How should healthcare organisations use segmentation to reduce device exploitability?

How segmentation changes the attack surface for clinical devices

Segmentation is most effective when it is treated as an exposure-reduction control, not a compensating fix for weak device security. In healthcare environments, the value comes from shrinking who and what can talk to a device, limiting east-west movement, and separating clinical technology from general-purpose user, administrative and vendor paths. That reduces the number of reachable attack surfaces an exploiter can use.

Segmentation works best when it is based on real dependencies, not just VLAN labels. A medical device may need only a narrow set of protocols to a clinical application, update service, time source or management enclave. If those dependencies are not mapped first, organisations either overexpose the device or block legitimate workflows and create unsafe exceptions.

Effective segmentation also needs to reflect device criticality. Life-support, imaging, infusion and monitoring systems usually deserve tighter trust boundaries than low-risk peripherals because the operational impact of abuse is much higher. The practical goal is to ensure that any permitted path is intentional, minimal and reviewable, rather than inherited from a flat hospital network design.

Why discovery, dependency mapping and policy enforcement must work together

Segmentation fails when teams try to enforce policy before they understand the environment. Device discovery tells you what is actually connected, dependency mapping shows what each device truly needs, and policy enforcement turns that knowledge into allowlisted traffic paths. If any one of those is missing, the organisation either misses hidden exposure or creates fragile controls that are bypassed during operations.

The hardest part is usually the gap between how devices are assumed to behave and how they really behave. Clinical engineering, biomedical teams, network teams and security teams often have different views of what is “required” communication. A mature segmentation programme reconciles those views into a narrow, documented policy set that can be defended during change, audit and incident response.

Segmentation is also more durable when it is verified continuously. Device fleets change, software is patched, remote support needs evolve, and temporary exceptions tend to become permanent. Without ongoing validation, the network control slowly drifts away from the original security intent and the device becomes reachable from paths that were never meant to exist.

What good healthcare segmentation actually looks like in practice

Good segmentation is intentionally boring. A device should be reachable only from the systems and user groups that must interact with it, and only over the minimum services needed for care delivery. That usually means separating clinical devices from office IT, limiting access from vendor channels, and isolating management traffic from patient-care traffic. NIST’s guidance on zero trust and OT segmentation is useful here because it frames access as an explicit trust decision rather than an assumed network property: NIST SP 800-207 Zero Trust Architecture and NIST SP 800-82 Rev 3, OT Security Guide.

In healthcare, segmentation should also respect the operational differences between device types. A radiology system, a bedside monitor and a networked pump may all be “medical devices”, but their communication patterns, downtime tolerance and vendor dependencies are not the same. The safest segmentation designs create separate trust zones and transition points so a compromise in one device class does not automatically expose the rest.

Because many hospitals still have legacy equipment, segmentation often becomes the most realistic control for reducing exploitability when patching is slow or constrained. That does not make segmentation a substitute for vendor remediation, but it does buy time by forcing an attacker to solve additional access problems before they can reach the device or move laterally from it.

Risk and Threat Considerations

Unsegmented clinical networks create two linked problems: broad reachable exposure for the device itself, and a much larger blast radius if the device is compromised. Attackers and opportunistic malware can abuse flat trust relationships to discover devices, reach management interfaces, and pivot into adjacent systems that support clinical operations.

Failure mechanism: Excessive connectivity, shared management paths, and undocumented exceptions allow attacker traffic to blend with legitimate hospital communications, which makes exploitation and lateral movement easier to perform and harder to detect.

Impact: A compromised device can become a foothold for service disruption, patient-care interruption, credential capture, or movement toward more sensitive clinical or administrative systems.

Practitioner Guidance

What to prioritise: Start with the devices whose compromise would create the highest operational or patient-safety consequence, then segment outward from those trust zones. If you cannot yet isolate everything, remove the most dangerous unnecessary paths first, especially broad inbound access and unmanaged vendor connectivity.

What to verify: Validate segmentation against observed device dependencies, not assumptions. The control is working only if you can show that essential clinical traffic still flows while non-essential routes are blocked and exceptions are time-bound, approved and reviewed.

What practitioners underestimate: Segmentation gets weakened most often by convenience-driven exceptions and by incomplete asset visibility. If you do not continuously reconcile discovered devices, communications and policy drift, the network will slowly revert to a flatter, more exploitable state.

Practitioner takeaway: For healthcare devices, segmentation should be judged by how much it reduces reachable paths and lateral movement opportunities, not by how neat the topology looks on paper.

Related resources from NHI Mgmt Group

• How should organisations use device trust in privileged access decisions?
• When should organisations use CIEM to reduce risk?
• How can organisations reduce risk when both SAML and OIDC are in use?
• How can teams reduce risk when agents use webcam or device-like inputs during testing?